Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Noel Alpins, ESCRS 2019 – PROWL LASIK Suprises 

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 27th 2019

We were delighted to meet up with Noel Alpins (NewVision Clinic, Victoria, Australia) again to hear about the PROWL-1 and PROWL-2 studies, and reports the patients most likely to benefit from LASIK vector planning.

Questions:
1. What were the aims of the PROWL-1 and PROWL-2 studies? (0:04)
2. What were the incidences of glare, starburst and halos in these studies? (2:00)
3. What are the causes of glare and halos? (3:34)
4. How can we reduce the incidence of glare and halos after LASIK? (4:40)
5. Which patients are likely to benefit most from LASIK vector planning and in whom is it contraindicated? (6:06)

Support: No funding was received in the production of this video.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup